My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 141

    1.

    Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model.

    Cahill S, Smyth P, Denning K, Flavin R, Li J, Potratz A, Guenther SM, Henfrey R, O'Leary JJ, Sheils O.

    Mol Cancer. 2007 Mar 13;6:21.PMID: 17355635 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model.

    Cahill S, Smyth P, Finn SP, Denning K, Flavin R, O'Regan EM, Li J, Potratz A, Guenther SM, Henfrey R, O'Leary JJ, Sheils O.

    Mol Cancer. 2006 Dec 11;5:70.PMID: 17156473 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.

    Sheu SY, Grabellus F, Schwertheim S, Handke S, Worm K, Schmid KW.

    Horm Metab Res. 2009 Jun;41(6):482-7. Epub 2009 Apr 15.PMID: 19370505 [PubMed - indexed for MEDLINE]Related articles

    4.

    Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.

    Brzeziańska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E, Lewiński A.

    Neuro Endocrinol Lett. 2007 Aug;28(4):351-9.PMID: 17693984 [PubMed - indexed for MEDLINE]Related articles

    5.

    Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling.

    Aherne ST, Smyth PC, Flavin RJ, Russell SM, Denning KM, Li JH, Guenther SM, O'Leary JJ, Sheils OM.

    Mol Cancer. 2008 Dec 4;7:89.PMID: 19055826 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.

    Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K.

    Pathol Int. 2007 Jan;57(1):12-20.PMID: 17199737 [PubMed - indexed for MEDLINE]Related articles

    7.

    BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.

    Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ.

    Thyroid. 2009 Apr;19(4):347-54.PMID: 19355825 [PubMed - indexed for MEDLINE]Related articles

    8.

    BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.

    Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R.

    Endocr Relat Cancer. 2008 Jun;15(2):511-20.PMID: 18509003 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.

    Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ, Cerutti JM.

    Clin Cancer Res. 2008 Aug 1;14(15):4735-42.PMID: 18676742 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.

    Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA, Zhang L, Taira K, Fagin JA.

    Endocrinology. 2006 Feb;147(2):1014-9. Epub 2005 Oct 27.PMID: 16254036 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.

    Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N.

    Mol Cancer Ther. 2007 Mar;6(3):1070-8.PMID: 17363500 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues.

    Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, Livolsi VA, Baloch ZW.

    Endocr Pathol. 2007 Fall;18(3):163-73.PMID: 18058265 [PubMed - indexed for MEDLINE]Related articles

    13.

    BRAF mutations in papillary thyroid carcinoma.

    Wojciechowska K, Lewinski A.

    Endocr Regul. 2006 Dec;40(4):129-38. Review.PMID: 17201587 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.

    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.

    Cancer. 2007 Sep 15;110(6):1218-26.PMID: 17685465 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.

    Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA.

    Cancer Res. 2006 Jul 1;66(13):6521-9.PMID: 16818623 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.

    Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.

    J Pathol. 2009 Apr;217(5):707-15.PMID: 19156774 [PubMed - indexed for MEDLINE]Related articles

    17.

    The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.

    Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.

    Cancer Res. 2009 Nov 1;69(21):8317-25. Epub 2009 Oct 27.PMID: 19861538 [PubMed - indexed for MEDLINE]Related articles

    18.

    BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

    Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.PMID: 18070147 [PubMed - indexed for MEDLINE]Related articles

    19.

    [BRAF initiating mutations in the papillary thyroid carcinoma]

    Rusinek D, Gubała E.

    Endokrynol Pol. 2006 Jul-Aug;57(4):438-44. Review. Polish. PMID: 17006850 [PubMed - indexed for MEDLINE]Related articles

    20.

    The role of microRNA genes in papillary thyroid carcinoma.

    He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A.

    Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80. Epub 2005 Dec 19.PMID: 16365291 [PubMed - indexed for MEDLINE]Related articlesFree article

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination
    Write to the Help Desk